Astel­las signs on pluripo­tent stem cell part­ners at Ex­CellThera; Lit­tle Uni­cy­cive brings home $25M af­ter float­ing a small IPO

Astel­las has signed up on rights for a batch of pluripo­tent stem cells from Mon­tre­al-based Ex­CellThera, cen­ter­ing on the in vit­ro use of their UM171 com­pound.

Astel­las is hand­ing over an un­spec­i­fied up­front pay­ment and promis­ing a slate of mile­stones to get the col­lab­o­ra­tion un­der­way.

Guy Sauvageau, CEO and founder of Ex­CellThera, not­ed:

While Ex­CellThera has fo­cused on de­vel­op­ing our core strength in oth­er ther­a­peu­tic ar­eas, Astel­las has in­vest­ed sig­nif­i­cant­ly in PSC-re­lat­ed pro­grams and is ab­solute­ly the right part­ner for us in that re­gard.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER